A Stock Recent News

Agilent's (A) fiscal third-quarter results reflect weakness across the Pharma, Food, Chemical and Advanced Materials, and Academic and Government markets.

Agilent Technologies, Inc. A posted better-than-expected third-quarter earnings and issued upbeat fourth-quarter guidance on Wednesday.

Agilent Technologies (NYSE: A ) just reported results for the third quarter of 2024. Agilent Technologies reported earnings per share of $1.32.

Agilent Technologies, Inc. (NYSE:A ) Q3 2024 Earnings Conference Call August 21, 2024 4:30 PM ET Company Participants Conference Call Participants Operator Ladies and gentlemen, welcome to the Agilent Technologies Q3 2024 Earnings Call. My name is Regina and I will be coordinating your call today.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.58 billion for the third quarter ended July 31, 2024, a decline of 5.6% reported and 4.4% core(1) compared to the third quarter of 2023. Third-quarter GAAP net income was $282 million, or $0.97 per share. This compares with $111 million, or $0.38 per share, in the third quarter of fiscal year 2023. Non-GAAP(2) net income was $385 million, or $1.32 per share during the quarter, compared with $4.

Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc., (NYSE: A) today announced that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid in identifying patients with synovial sarcoma who may be eligible for treatment with TECELRA® (afamitresgene autoleucel, also known as afami-cel or ADP-A2M4), a MAGE-A4-directed engineered TCR T-Cell therapy. MAGE-A4 (melanoma-associated antigen A4) is a cancer-testis antigen overexpressed in vario.

Statement Pursuant to Section 19(a) of the Investment Company Act of 1940 DENVER, CO / ACCESSWIRE / July 31, 2024 / On July 31, 2024, SRH Total Return Fund, Inc. (NYSE:STEW) (the "Fund"), a closed-end investment company, will pay a distribution on its common stock of $0.1375 per share to stockholders of record at the close of business on July 24, 2024. The Fund, acting in accordance with an exemptive order received from the Securities and Exchange Commission and with approval of its Board of Directors, adopted a managed distribution policy under which the Fund may utilize capital gains, where applicable, as part of regular quarterly cash distributions to its stockholders.

Statement Pursuant to Section 19(a) of the Investment Company Act of 1940 DENVER, CO / ACCESSWIRE / July 31, 2024 / On July 31, 2024, the Clough Global Opportunities Fund (NYSE American:GLO) (the "Fund"), a closed-end fund, paid a monthly distribution on its common stock of $0.0480 per share to shareholders of record at the close of business on July 19, 2024. The following table sets forth the estimated amount of the sources of distribution for purposes of Section 19 of the Investment Company Act of 1940, as amended, and the related rules adopted thereunder.

Agilent (A) unveils its new ProteoAnalyzer system in a bid to strengthen its Diagnostics and Genomics Group segment.